Navigating CLL Treatment Choices

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL,Matthew Davids, MD, MMSc

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

EP: 6.Latest Trends and Innovations in CLL and MCL Treatment

EP: 7.CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors

Now Viewing

EP: 8.Navigating CLL Treatment Choices

What factors do you consider when selecting between BTK inhibitors and venetoclax plus obinutuzumab for CLL?
If selecting a BTK inhibitor, what factors do you consider when selecting among acalabrutinib, zanubrutinib, and ibrutinib?
With the availability of targeted therapies, what role does cytotoxic chemotherapy play in the treatment of CLL?